节律制药

关于 Rhythm Pharmaceuticals

Rhythm 制药, Inc. is a commercial-stage biopharmaceutical company, which 从事 the 开发 and commercialization of therapeutics for patients with rare diseases. The firm 提供 IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also 参与 the clinical 开发 program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was 成立 by Bart Henderson in November 2008 and is 总部位于 in Boston, MA.

成立时间

2008

首席执行官

Dr. David P. Meeker,M.D.

员工人数

414

总部地址

Boston, Massachusetts, United States of America

财年结束日

12-31

官方网站

rhythmtx.com

公司概况

交易所

US

股票代码

RYTM

市值排名

#1874

上市日期

2017-10-05

市值

5.93B

流通市值

4.83B

总股数

68.85M

流通股数

56.04M

行业与主题板块

浏览全部行业与主题板块